Competitive Inhibitors of Enzymes and Their Therapeutic Application
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
pharmaceutics Review Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice Malavika Deodhar 1, Sweilem B Al Rihani 1 , Meghan J. Arwood 1, Lucy Darakjian 1, Pamela Dow 1 , Jacques Turgeon 1,2 and Veronique Michaud 1,2,* 1 Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA; [email protected] (M.D.); [email protected] (S.B.A.R.); [email protected] (M.J.A.); [email protected] (L.D.); [email protected] (P.D.); [email protected] (J.T.) 2 Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada * Correspondence: [email protected]; Tel.: +1-856-938-8697 Received: 5 August 2020; Accepted: 31 August 2020; Published: 4 September 2020 Abstract: In an ageing society, polypharmacy has become a major public health and economic issue. Overuse of medications, especially in patients with chronic diseases, carries major health risks. One common consequence of polypharmacy is the increased emergence of adverse drug events, mainly from drug–drug interactions. The majority of currently available drugs are metabolized by CYP450 enzymes. Interactions due to shared CYP450-mediated metabolic pathways for two or more drugs are frequent, especially through reversible or irreversible CYP450 inhibition. The magnitude of these interactions depends on several factors, including varying affinity and concentration of substrates, time delay between the administration of the drugs, and mechanisms of CYP450 inhibition. Various types of CYP450 inhibition (competitive, non-competitive, mechanism-based) have been observed clinically, and interactions of these types require a distinct clinical management strategy. This review focuses on mechanism-based inhibition, which occurs when a substrate forms a reactive intermediate, creating a stable enzyme–intermediate complex that irreversibly reduces enzyme activity. -
Polyamine Biosynthesis in Human Fetal Liver and Brain
Pediat. Res. 8: 231-237 (1974) S-Adenosylmethionine decarboxylase polyamines developmental biochemistry putrescine fetus spermidine ornithine decarboxylase Polyamine Biosynthesis in Human Fetal Liver and Brain JOHN A. STURMAN'~~]AND GERALD E. GAULL Department of Pediatric Research, Institute for Basic liesearch in Mental Retardation, Staten Island, and Department of Pediatrics, Division of Medical Genetics and Clinical Genetics Center, Mount Sinai School of Medicine of the City University of New York, New York, New York, USA Extract S-Adenosylmethionine decarboxylase specific activity in fetal (9.0-25.0 cm crown- rump length) human liver was 20-fold greater than in mature human liver, both in the absence of putrescine (63.1 f 7.2 versus 3.5 =t 0.8 pmol C02/mgprotein/30 min) or in the presence of putrescine (1 16.9 + 8.2 uersus 6.2 =I= 1.0 pmol C02/mg protein/30 min). Extracts of fetal human brain did not have a significantly greater specific ac- tivity of S-adenosylmethionine decarboxylase than extracts of mature human brain when assayed in the absence of putrescine and had less when assayed in the presence of putrescine (84.7 =t 14.9 versus 175.5 f 30.6 pmol C02/mgprotein/30 min). Ornithine decarboxylase specific activity was greater in fetal liver than in mature liver (8.8 =t1.6 versus 1.1 f 0.3 pmol CO 2/mg protein/30 min) and 20-fold greater in fetal brain than in mature brain (7 1.2 =t 12.1 uersus 3.1 =I= 1.4 pmol CO z/mg protein/30 min). -
Potent Inhibition of Monoamine Oxidase B by a Piloquinone from Marine-Derived Streptomyces Sp. CNQ-027
J. Microbiol. Biotechnol. (2017), 27(4), 785–790 https://doi.org/10.4014/jmb.1612.12025 Research Article Review jmb Potent Inhibition of Monoamine Oxidase B by a Piloquinone from Marine-Derived Streptomyces sp. CNQ-027 Hyun Woo Lee1, Hansol Choi2, Sang-Jip Nam2, William Fenical3, and Hoon Kim1* 1Department of Pharmacy and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea 2Department of Chemistry and Nano Science, Ewha Womans University, Seoul 03760, Republic of Korea 3Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, La Jolla, CA 92093-0204, USA Received: December 19, 2016 Revised: December 27, 2016 Two piloquinone derivatives isolated from Streptomyces sp. CNQ-027 were tested for the Accepted: January 4, 2017 inhibitory activities of two isoforms of monoamine oxidase (MAO), which catalyzes monoamine neurotransmitters. The piloquinone 4,7-dihydroxy-3-methyl-2-(4-methyl-1- oxopentyl)-6H-dibenzo[b,d]pyran-6-one (1) was found to be a highly potent inhibitor of First published online human MAO-B, with an IC50 value of 1.21 µM; in addition, it was found to be highly effective January 9, 2017 against MAO-A, with an IC50 value of 6.47 µM. Compound 1 was selective, but not extremely *Corresponding author so, for MAO-B compared with MAO-A, with a selectivity index value of 5.35. Compound 1,8- Phone: +82-61-750-3751; dihydroxy-2-methyl-3-(4-methyl-1-oxopentyl)-9,10-phenanthrenedione (2) was moderately Fax: +82-61-750-3708; effective for the inhibition of MAO-B (IC = 14.50 µM) but not for MAO-A (IC > 80 µM). -
(12) Patent Application Publication (10) Pub. No.: US 2009/0292100 A1 Fiene Et Al
US 20090292100A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0292100 A1 Fiene et al. (43) Pub. Date: Nov. 26, 2009 (54) PROCESS FOR PREPARING (86). PCT No.: PCT/EP07/57646 PENTAMETHYLENE 1.5-DIISOCYANATE S371 (c)(1), (75) Inventors: Martin Fiene, Niederkirchen (DE): (2), (4) Date: Jan. 9, 2009 (DE);Eckhard Wolfgang Stroefer, Siegel, Mannheim (30) Foreign ApplicationO O Priority Data Limburgerhof (DE); Stephan Aug. 1, 2006 (EP) .................................. O61182.56.4 Freyer, Neustadt (DE); Oskar Zelder, Speyer (DE); Gerhard Publication Classification Schulz, Bad Duerkheim (DE) (51) Int. Cl. Correspondence Address: CSG 18/00 (2006.01) OBLON, SPIVAK, MCCLELLAND MAIER & CD7C 263/2 (2006.01) NEUSTADT, L.L.P. CI2P I3/00 (2006.01) 194O DUKE STREET CD7C 263/10 (2006.01) ALEXANDRIA, VA 22314 (US) (52) U.S. Cl. ........... 528/85; 560/348; 435/128; 560/347; 560/355 (73) Assignee: BASFSE, LUDWIGSHAFEN (DE) (57) ABSTRACT (21) Appl. No.: 12/373,088 The present invention relates to a process for preparing pen tamethylene 1,5-diisocyanate, to pentamethylene 1,5-diiso (22) PCT Filed: Jul. 25, 2007 cyanate prepared in this way and to the use thereof. US 2009/0292100 A1 Nov. 26, 2009 PROCESS FOR PREPARING ene diisocyanates, especially pentamethylene 1,4-diisocyan PENTAMETHYLENE 1.5-DIISOCYANATE ate. Depending on its preparation, this proportion may be up to several % by weight. 0014. The pentamethylene 1,5-diisocyanate prepared in 0001. The present invention relates to a process for pre accordance with the invention has, in contrast, a proportion of paring pentamethylene 1,5-diisocyanate, to pentamethylene the branched pentamethylene diisocyanate isomers of in each 1.5-diisocyanate prepared in this way and to the use thereof. -
Evidence of Pyrimethamine and Cycloguanil Analogues As Dual Inhibitors of Trypanosoma Brucei Pteridine Reductase and Dihydrofolate Reductase
pharmaceuticals Article Evidence of Pyrimethamine and Cycloguanil Analogues as Dual Inhibitors of Trypanosoma brucei Pteridine Reductase and Dihydrofolate Reductase Giusy Tassone 1,† , Giacomo Landi 1,†, Pasquale Linciano 2,† , Valeria Francesconi 3 , Michele Tonelli 3 , Lorenzo Tagliazucchi 2 , Maria Paola Costi 2 , Stefano Mangani 1 and Cecilia Pozzi 1,* 1 Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018–2022, University of Siena, via Aldo Moro 2, 53100 Siena, Italy; [email protected] (G.T.); [email protected] (G.L.); [email protected] (S.M.) 2 Department of Life Science, University of Modena and Reggio Emilia, via Campi 103, 41125 Modena, Italy; [email protected] (P.L.); [email protected] (L.T.); [email protected] (M.P.C.) 3 Department of Pharmacy, University of Genoa, Viale Benedetto XV n.3, 16132 Genoa, Italy; [email protected] (V.F.); [email protected] (M.T.) * Correspondence: [email protected]; Tel.: +39-0577-232132 † These authors contributed equally to this work. Abstract: Trypanosoma and Leishmania parasites are the etiological agents of various threatening Citation: Tassone, G.; Landi, G.; neglected tropical diseases (NTDs), including human African trypanosomiasis (HAT), Chagas disease, Linciano, P.; Francesconi, V.; Tonelli, and various types of leishmaniasis. Recently, meaningful progresses in the treatment of HAT, due to M.; Tagliazucchi, L.; Costi, M.P.; Trypanosoma brucei (Tb), have been achieved by the introduction of fexinidazole and the combination Mangani, S.; Pozzi, C. Evidence of therapy eflornithine–nifurtimox. Nevertheless, due to drug resistance issues and the exitance of Pyrimethamine and Cycloguanil animal reservoirs, the development of new NTD treatments is still required. -
Insights Into the Role of Tick Salivary Protease Inhibitors During Ectoparasite–Host Crosstalk
International Journal of Molecular Sciences Review Insights into the Role of Tick Salivary Protease Inhibitors during Ectoparasite–Host Crosstalk Mohamed Amine Jmel 1,† , Hajer Aounallah 2,3,† , Chaima Bensaoud 1, Imen Mekki 1,4, JindˇrichChmelaˇr 4, Fernanda Faria 3 , Youmna M’ghirbi 2 and Michalis Kotsyfakis 1,* 1 Laboratory of Genomics and Proteomics of Disease Vectors, Biology Centre CAS, Institute of Parasitology, Branišovská 1160/31, 37005 Ceskˇ é Budˇejovice,Czech Republic; [email protected] (M.A.J.); [email protected] (C.B.); [email protected] (I.M.) 2 Institut Pasteur de Tunis, Université de Tunis El Manar, LR19IPTX, Service d’Entomologie Médicale, Tunis 1002, Tunisia; [email protected] (H.A.); [email protected] (Y.M.) 3 Innovation and Development Laboratory, Innovation and Development Center, Instituto Butantan, São Paulo 05503-900, Brazil; [email protected] 4 Faculty of Science, University of South Bohemia in Ceskˇ é Budˇejovice, 37005 Ceskˇ é Budˇejovice, Czech Republic; [email protected] * Correspondence: [email protected] † These authors contributed equally. Abstract: Protease inhibitors (PIs) are ubiquitous regulatory proteins present in all kingdoms. They play crucial tasks in controlling biological processes directed by proteases which, if not tightly regulated, can damage the host organism. PIs can be classified according to their targeted proteases or their mechanism of action. The functions of many PIs have now been characterized and are showing clinical relevance for the treatment of human diseases such as arthritis, hepatitis, cancer, AIDS, and cardiovascular diseases, amongst others. Other PIs have potential use in agriculture as insecticides, anti-fungal, and antibacterial agents. -
Sequence Requirement for Peptide Recognition by Rat Brain P2lras Protein Farnesyltransferase
Proc. Natl. Acad. Sci. USA Vol. 88, pp. 732-736, February 1991 Biochemistry Sequence requirement for peptide recognition by rat brain p2lras protein farnesyltransferase (covalent modification/prenylation/mevalonate/tetrapeptides/enzyme inhibition) YUVAL REISS*, SARAH J. STRADLEYt, LILA M. GIERASCHt, MICHAEL S. BROWN*, AND JOSEPH L. GOLDSTEIN* Departments of *Molecular Genetics and tPharmacology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235 Contributed by Michael S. Brown, October 30, 1990 ABSTRACT We tested 42 tetrapeptides for their ability to a heterodimer (10, 11). The enzyme recognizes sequences as bind to the rat brain p2l' protein farnesyltransferase as short as four amino acids provided that cysteine is at the estimated by their ability to compete with p2lH"- in a farnesyl- fourth position from the COOH terminus. Recognition was transfer assay. Peptides with the highest affinity had the struc- demonstrated by the ability ofthese peptides to compete with ture Cys-Al-A2-X, where positions Al and A2 are occupied by p21Ha-ras in the protein farnesyltransferase assay. In addition, aliphatic amino acids and position X is-occupied by a COOH- the enzyme adhered to an affinity column containing a terminal methionine, serine, or phenylalanine. Charged resi- hexapeptide corresponding to the COOH-terminal sequence dues reduced affinity slightly at the Al position and much more of p2lKi-msB. A similar enzymatic activity was identified by drastically at the A2 and X positions. Effective inhibitors in- Schaber et al. (12) in crude extracts of bovine brain. cluded tetrapeptides corresponding to the COOH termini of all The above findings suggest that the recognition site for the animal cell proteins known to be farnesylated. -
Discovery and Characterization of Blse, a Radical S- Adenosyl-L-Methionine Decarboxylase Involved in the Blasticidin S Biosynthetic Pathway
Discovery and Characterization of BlsE, a Radical S- Adenosyl-L-methionine Decarboxylase Involved in the Blasticidin S Biosynthetic Pathway Jun Feng1, Jun Wu1, Nan Dai2, Shuangjun Lin1, H. Howard Xu3, Zixin Deng1, Xinyi He1* 1 State Key Laboratory of Microbial Metabolism and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China, 2 New England Biolabs, Inc., Research Department, Ipswich, Massachusetts, United States of America, 3 Department of Biological Sciences, California State University Los Angeles, Los Angeles, California, United States of America Abstract BlsE, a predicted radical S-adenosyl-L-methionine (SAM) protein, was anaerobically purified and reconstituted in vitro to study its function in the blasticidin S biosynthetic pathway. The putative role of BlsE was elucidated based on bioinformatics analysis, genetic inactivation and biochemical characterization. Biochemical results showed that BlsE is a SAM-dependent radical enzyme that utilizes cytosylglucuronic acid, the accumulated intermediate metabolite in blsE mutant, as substrate and catalyzes decarboxylation at the C5 position of the glucoside residue to yield cytosylarabinopyranose. Additionally, we report the purification and reconstitution of BlsE, characterization of its [4Fe–4S] cluster using UV-vis and electron paramagnetic resonance (EPR) spectroscopic analysis, and investigation of the ability of flavodoxin (Fld), flavodoxin 2+ reductase (Fpr) and NADPH to reduce the [4Fe–4S] cluster. Mutagenesis studies demonstrated that Cys31, Cys35, Cys38 in the C666C6MC motif and Gly73, Gly74, Glu75, Pro76 in the GGEP motif were crucial amino acids for BlsE activity while mutation of Met37 had little effect on its function. Our results indicate that BlsE represents a typical [4Fe–4S]-containing radical SAM enzyme and it catalyzes decarboxylation in blasticidin S biosynthesis. -
Angiotensin-I-Converting Enzyme Inhibitory Activity of Coumarins from Angelica Decursiva
molecules Article Angiotensin-I-Converting Enzyme Inhibitory Activity of Coumarins from Angelica decursiva 1,2,3,4, 1, 5, 1, Md Yousof Ali y, Su Hui Seong y , Hyun Ah Jung * and Jae Sue Choi * 1 Department of Food and Life Science, Pukyong National University, Busan 48513, Korea; [email protected] (M.Y.A.); [email protected] (S.H.S.) 2 Department of Chemistry and Biochemistry, Concordia University, Montreal, QC H4B 1R6, Canada 3 Department of Biology, Faculty of Arts and Science, Concordia University, 7141 Sherbrooke St. W., Montreal, QC H4B 1R6, Canada 4 Centre for Structural and Functional Genomic, Department of Biology, Faculty of Arts and Science, Concordia University, 7141 Sherbrooke St. W., Montreal, QC H4B 1R6, Canada 5 Department of Food Science and Human Nutrition, Jeonbuk National University, Jeonju 54896, Korea * Correspondence: [email protected] (H.A.J.); [email protected] (J.S.C.); Tel.: +82-63-270-4882 (H.A.J.); +82-51-629-5845 (J.S.C.) These authors contributed equally to this work. y Academic Editor: Rachid Skouta Received: 11 October 2019; Accepted: 30 October 2019; Published: 31 October 2019 Abstract: The bioactivity of ten traditional Korean Angelica species were screened by angiotensin-converting enzyme (ACE) assay in vitro. Among the crude extracts, the methanol extract of Angelica decursiva whole plants exhibited potent inhibitory effects against ACE. In addition, the ACE inhibitory activity of coumarins 1–5, 8–18 was evaluated, along with two phenolic acids (6, 7) obtained from A. decursiva. Among profound coumarins, 11–18 were determined to manifest marked inhibitory activity against ACE with IC50 values of 4.68–20.04 µM. -
Phytohormones Regulate Accumulation of Osmolytes Under Abiotic Stress
biomolecules Review Phytohormones Regulate Accumulation of Osmolytes Under Abiotic Stress Anket Sharma 1,* , Babar Shahzad 2, Vinod Kumar 3 , Sukhmeen Kaur Kohli 4, Gagan Preet Singh Sidhu 5, Aditi Shreeya Bali 6, Neha Handa 7 , Dhriti Kapoor 7, Renu Bhardwaj 4 and Bingsong Zheng 1,* 1 State Key Laboratory of Subtropical Silviculture, Zhejiang A&F University, Hangzhou 311300, China 2 School of Land and Food, University of Tasmania, Hobart, Tasmania 7005, Australia 3 Department of Botany, DAV University, Sarmastpur, Jalandhar 144012, Punjab, India 4 Plant Stress Physiology Laboratory, Department of Botanical & Environmental Sciences, Guru Nanak Dev University, Amritsar 143005, India 5 Department of Environment Education, Government College of Commerce and Business Administration, Chandigarh 160047, India 6 Mehr Chand Mahajan D.A.V. College for Women, Chandigarh 160036, India 7 School of Bioengineering & Biosciences, Lovely Professional University, Phagwara 144411, India * Correspondence: [email protected] (A.S.); [email protected] (B.Z.); Tel.: +86-(0)-5716-373-0936 (B.Z.) Received: 13 June 2019; Accepted: 16 July 2019; Published: 17 July 2019 Abstract: Plants face a variety of abiotic stresses, which generate reactive oxygen species (ROS), and ultimately obstruct normal growth and development of plants. To prevent cellular damage caused by oxidative stress, plants accumulate certain compatible solutes known as osmolytes to safeguard the cellular machinery. The most common osmolytes that play crucial role in osmoregulation are proline, glycine-betaine, polyamines, and sugars. These compounds stabilize the osmotic differences between surroundings of cell and the cytosol. Besides, they also protect the plant cells from oxidative stress by inhibiting the production of harmful ROS like hydroxyl ions, superoxide ions, hydrogen peroxide, and other free radicals. -
Bacterial Tropone Natural Products and Derivatives
Reviews ChemBioChem doi.org/10.1002/cbic.201900786 1 2 3 Bacterial Tropone Natural Products and Derivatives: 4 5 Overview of their Biosynthesis, Bioactivities, Ecological Role 6 and Biotechnological Potential 7 8 Ying Duan,[a] Melanie Petzold,[a] Raspudin Saleem-Batcha,[a] and Robin Teufel*[a] 9 10 11 Tropone natural products are non-benzene aromatic com- sulfur among other reactions. Tropones play important roles in 12 pounds of significant ecological and pharmaceutical interest. the terrestrial and marine environment where they act as 13 Herein, we highlight current knowledge on bacterial tropones antibiotics, algaecides, or quorum sensing signals, while their 14 and their derivatives such as tropolones, tropodithietic acid, bacterial producers are often involved in symbiotic interactions 15 and roseobacticides. Their unusual biosynthesis depends on a with plants and marine invertebrates (e.g., algae, corals, 16 universal CoA-bound precursor featuring a seven-membered sponges, or mollusks). Because of their potent bioactivities and 17 carbon ring as backbone, which is generated by a side reaction of slowly developing bacterial resistance, tropones and their 18 of the phenylacetic acid catabolic pathway. Enzymes encoded derivatives hold great promise for biomedical or biotechnolog- 19 by separate gene clusters then further modify this key ical applications, for instance as antibiotics in (shell)fish 20 intermediate by oxidation, CoA-release, or incorporation of aquaculture. 21 22 23 1. Introduction pathways and unforeseen enzyme reactions may impair 24 detection and structural predictions.[3] 25 Structurally diverse natural products are typically generated by A remarkable case of such a noncanonical biosynthetic 26 dedicated secondary metabolic pathways that mostly operate route is found for bacterial tropone (9) natural products and 27 in microbes and plants. -
Pathogen Xylella Fastidiosa
articles The genome sequence of the plant pathogen Xylella fastidiosa The Xylella fastidiosa Consortium of the Organization for Nucleotide Sequencing and Analysis*,Sa˜o Paulo, Brazil * A full list of authors appears at the end of this paper ............................................................................................................................................................................................................................................................................ Xylella fastidiosa is a fastidious, xylem-limited bacterium that causes a range of economically important plant diseases. Here we report the complete genome sequence of X. fastidiosa clone 9a5c, which causes citrus variegated chlorosis—a serious disease of orange trees. The genome comprises a 52.7% GC-rich 2,679,305-base-pair (bp) circular chromosome and two plasmids of 51,158 bp and 1,285 bp. We can assign putative functions to 47% of the 2,904 predicted coding regions. Efficient metabolic functions are predicted, with sugars as the principal energy and carbon source, supporting existence in the nutrient-poor xylem sap. The mechanisms associated with pathogenicity and virulence involve toxins, antibiotics and ion sequestration systems, as well as bacterium–bacterium and bacterium–host interactions mediated by a range of proteins. Orthologues of some of these proteins have only been identified in animal and human pathogens; their presence in X. fastidiosa indicates that the molecular basis for bacterial pathogenicity is both conserved and independent of host. At least 83 genes are bacteriophage-derived and include virulence-associated genes from other bacteria, providing direct evidence of phage-mediated horizontal gene transfer. Citrus variegated chlorosis (CVC), which was first recorded in Brazil meningitidis10 (53.7%). This may reflect the lack of previous in 1987, affects all commercial sweet orange varieties1. Symptoms complete genome sequences from phytopathogenic bacteria.